Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Linde Gas & Equipment Inc. announced today the submission of a 510(k) premarket notification application with the U.S. Food and Drug Administration (FDA) for NOXBOX® I PLUS, a nitric oxide delivery ...

Target population is men with mCRPC who have had no treatment with newer, potent AR signaling inhibitors including darolutamide, enzalutamide ... nuclear medicine, nurses, psychologists, and ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Staffing and certain compliance issues related to updated survey guidance coming in late March, particularly those that relate to patient discharges as ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...